16 September 2025
16 September 2025
Novartis has joined the swathe of big pharma companies bolstering their molecular glue degrader portfolios.
Rybelsus becomes the first oral glucagon-like peptide-1 receptor agonist in the EU with proven cardiovascular benefits.
Cadrenal will acquire eXIthera’s intravenous Factor XIa inhibitor frunexian, oral inhibitor EP-7327, and additional novel FXIa small molecules.
Despite missing the primary endpoint, aTyr Pharma still sees a future for the drug as it plans further FDA discussions.
The British drugmaker shelved a separate £450m ($612m) investment in a vaccine manufacturing plant in northern England, earlier this year.
FDA chief Martin Makary said the agency will now ‘proactively monitor’ pharma companies for advertising law breaches.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
